Shelter Pharma

When is the next results date for Shelter Pharma?

No Upcoming Board Meetings

What is the technical trend for Shelter Pharma?

As of May 30, 2025, Shelter Pharma's technical trend is mildly bearish, indicated by daily moving averages and weekly Bollinger Bands, despite a mildly bullish MACD and no clear signals from the RSI or Dow Theory.

As of 30 May 2025, the technical trend for Shelter Pharma has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly Bollinger Bands also reflect a bearish outlook. The MACD on the weekly chart is mildly bullish, but this is countered by the lack of signals from the RSI on both weekly and monthly time frames. Additionally, the Dow Theory shows no trend in both weekly and monthly perspectives. Overall, the current stance is mildly bearish, driven primarily by the daily moving averages and weekly Bollinger Bands.

Who are the peers of the Shelter Pharma?

Peers of Shelter Pharma include Vasundhara Rasy., Concord Drugs, Lasa Supergeneri, Dipna Pharmachem, Medi Caps, Transchem, Sandu Pharma, Kabra Drugs, and Roopa Industries. Shelter Pharma has excellent management and capital structure, with a 1-year return of -24.86%, while Dipna Pharmachem leads with a 203.59% return.

Peers: The peers of Shelter Pharma are Vasundhara Rasy., Concord Drugs, Lasa Supergeneri, Dipna Pharmachem, Medi Caps, Transchem, Sandu Pharma., Kabra Drugs, Roopa Industries.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shelter Pharma, while Average management risk is found at Vasundhara Rasy. and Medi Caps, and the rest have Below Average management risk. Growth is Excellent at Dipna Pharmachem, Good at Shelter Pharma and Roopa Industries, Below Average at Vasundhara Rasy., Concord Drugs, Lasa Supergeneri, Medi Caps, Transchem, Sandu Pharma., and the rest, while Kabra Drugs does not qualify. Capital Structure is Excellent at Shelter Pharma, Good at Vasundhara Rasy. and Medi Caps, Average at Lasa Supergeneri, Below Average at Concord Drugs, Dipna Pharmachem, Transchem, Sandu Pharma., Roopa Industries, and the rest, while Kabra Drugs does not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Dipna Pharmachem at 203.59%, while the lowest is Lasa Supergeneri at -49.73%. Shelter Pharma's 1-year return is -24.86%, which is higher than Lasa Supergeneri but lower than Dipna Pharmachem. Additionally, the six-month return is negative for Medi Caps, Shelter Pharma, Lasa Supergeneri, and Roopa Industries.

What does Shelter Pharma do?

Shelter Pharma Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology sector, focused on manufacturing ayurvedic and herbal products. It was incorporated in 2007 and currently has a market cap of INR 51 Cr, with no recent sales or profit data reported.

Overview: <BR>Shelter Pharma Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry, primarily focused on manufacturing ayurvedic and herbal products.<BR><BR>History: <BR>Shelter Pharma Limited was incorporated on 12 October 2007, transitioning from a partnership firm named "M/s Shelter Pharma" to a public limited company. There is no recent sales or profit data reported.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 51 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 7.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.68% <BR>Debt-Equity: -0.12 <BR>Return on Equity: 20.21% <BR>Price-to-Book: 1.42 <BR><BR>Contact Details: <BR>Address: Not available <BR>Phone: Not available <BR>Email: Not available <BR>Website: Not available

Who are the top shareholders of the Shelter Pharma?

The top shareholders of Shelter Pharma include promoters, with Shakil Nisarahmed Sabugar holding the largest stake at 15.23%. Individual investors own 43.24% of the company, and there are no mutual funds or foreign institutional investors involved.

The top shareholders of Shelter Pharma primarily consist of promoters, with Shakil Nisarahmed Sabugar holding the highest stake at 15.23%. Individual investors collectively own 43.24% of the company. There are no mutual funds or foreign institutional investors (FIIs) holding shares in Shelter Pharma, and there are no pledged promoter holdings.

How big is Shelter Pharma?

As of 24th July, Shelter Pharma Ltd has a market capitalization of 52.00 Cr, classifying it as a Micro Cap company, with no valid financial data available for Net Sales and Net Profit for the latest four quarters. Shareholder's Funds are 35.82 Cr and Total Assets are 37.88 Cr as of March 2024.

As of 24th July, <BR><BR>Market Cap: Shelter Pharma Ltd has a market capitalization of 52.00 Cr, classifying it as a Micro Cap company. <BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters. <BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 35.82 Cr and Total Assets valued at 37.88 Cr.

Is Shelter Pharma overvalued or undervalued?

As of August 28, 2025, Shelter Pharma is considered undervalued with a valuation grade upgrade to very attractive, supported by a low PE ratio of 7.42 and an EV to EBIT of 5.03, significantly lower than its peers like Sun Pharma and Divi's Lab, despite a recent stock price decline.

As of 28 August 2025, Shelter Pharma's valuation grade has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued, especially when compared to its peers. Key ratios supporting this assessment include a PE ratio of 7.42, an EV to EBIT of 5.03, and a PEG ratio of 0.46, all of which are substantially lower than industry averages.<BR><BR>In comparison to its peers, Shelter Pharma stands out with a much lower PE ratio than Sun Pharma (33.18) and Divi's Lab (70.66), both of which are classified as expensive. Additionally, Shelter Pharma's EV to EBITDA ratio of 4.89 is significantly more attractive than that of its competitors, reinforcing its undervaluation. Despite a recent decline in stock price, Shelter Pharma has outperformed the Sensex over the past month, suggesting a potential rebound as market conditions stabilize.

Has Shelter Pharma declared dividend?

Shelter Pharma Ltd has declared a 3% dividend, with an ex-date of September 23, 2025. While recent total returns show positive growth in the short to medium term, longer-term returns have been stagnant with no dividends declared in the past few years.

Shelter Pharma Ltd has declared a 3% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 3%<BR>- Ex-date: 23 Sep 25<BR><BR>Dividend Yield: 0.67%.<BR><BR>Total Returns by Period:<BR>In the 3-month period, the price return was 9.9%, the dividend return was 0.75%, resulting in a total return of 10.65%.<BR><BR>In the 6-month period, the price return was 3.51%, the dividend return was 0.68%, leading to a total return of 4.19%.<BR><BR>For the 1-year period, the price return was 5.5%, the dividend return was 1.25%, which culminated in a total return of 6.75%.<BR><BR>Over the 2-year period, the price return was -3.95%, the dividend return was 1.32%, resulting in a total return of -2.63%.<BR><BR>In the 3-year period, there was no price return, no dividend return, and thus a total return of 0.0%.<BR><BR>For the 4-year period, there were no changes in price or dividends, leading to a total return of 0.0%.<BR><BR>In the 5-year period, again, there were no returns from price or dividends, resulting in a total return of 0.0%.<BR><BR>Overall, Shelter Pharma Ltd has declared a dividend, and while the recent total returns show positive growth in the short to medium term, longer-term returns have been stagnant with no dividends declared in the past few years.

How has been the historical performance of Shelter Pharma?

Shelter Pharma has shown consistent growth in net sales and profitability, with net sales increasing from INR 30.06 crore in March 2022 to INR 50.66 crore in March 2025, and profit after tax rising from INR 1.84 crore to INR 7.24 crore during the same period. The company's financial performance reflects a strong upward trend across key metrics.

Answer:<BR>The historical performance of Shelter Pharma shows a consistent growth trajectory in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Shelter Pharma's net sales have steadily increased from INR 30.06 crore in March 2022 to INR 50.66 crore in March 2025. This growth is accompanied by a rise in total operating income, which reached INR 50.66 crore in March 2025, up from INR 30.06 crore in March 2022. The company's total expenditure also grew, amounting to INR 40.59 crore in March 2025, compared to INR 27.38 crore in March 2022. Operating profit (PBDIT) has shown significant improvement, rising from INR 2.68 crore in March 2022 to INR 10.08 crore in March 2025, reflecting an operating profit margin of 19.88% in the latest fiscal year. Profit before tax increased from INR 2.51 crore in March 2022 to INR 9.68 crore in March 2025, with profit after tax also rising from INR 1.84 crore to INR 7.24 crore during the same period. The company's total assets grew from INR 12.84 crore in March 2022 to INR 48.30 crore in March 2025, while total liabilities increased from INR 12.84 crore to INR 48.30 crore, indicating a proportional growth in both assets and liabilities. Cash flow from operating activities improved significantly, reaching INR 5.00 crore in March 2025, compared to a negative cash flow of INR 1.00 crore in March 2024. Overall, Shelter Pharma demonstrates a robust upward trend in its financial performance across key metrics.

Why is Shelter Pharma Ltd falling/rising?

As of 13-Feb, Shelter Pharma Ltd's stock price is Rs 41.29, down 3.73% and part of a two-day decline totaling 4.02%. Investor participation has significantly decreased, indicating reduced confidence in the stock despite recent positive performance over the past week and month.

As of 13-Feb, Shelter Pharma Ltd's stock price is falling, currently at Rs 41.29, which reflects a decrease of Rs 1.6 or 3.73%. This decline is part of a broader trend, as the stock has been losing value for the last two days, with a total drop of 4.02% during this period. Additionally, the stock has underperformed its sector by 2.69% today.<BR><BR>Investor participation appears to be declining, as evidenced by a delivery volume of 0 on 12 February, which is a significant drop of 100% compared to the 5-day average delivery volume. This lack of trading activity may indicate reduced investor interest or confidence in the stock.<BR><BR>Despite some positive performance over the past week and month, where the stock has increased by 2.97% and 24.40% respectively, the current negative momentum and the recent consecutive falls suggest that the stock is facing downward pressure at this time.

Which are the latest news on Shelter Pharma?